DOCSLIB.ORG

Cellular Metabolism Regulates Anti-Oxidant Response Through ERK5-MEF2 Pathway Abrar Ul Haq Khan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cellular Metabolism Regulates Anti-Oxidant Response Through ERK5-MEF2 Pathway Abrar Ul Haq Khan Cellular Metabolism Regulates Anti-Oxidant Response Through ERK5-MEF2 Pathway Abrar Ul Haq Khan To cite this version: Abrar Ul Haq Khan. Cellular Metabolism Regulates Anti-Oxidant Response Through ERK5- MEF2 Pathway. Human health and pathology. Université Montpellier, 2017. English. NNT : 2017MONTT036. tel-01684254 HAL Id: tel-01684254 https://tel.archives-ouvertes.fr/tel-01684254 Submitted on 15 Jan 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Délivré par UNIVERSITE DE MONTPELLIER Préparée au sein de l’école doctorale CBS2 n°168 - Sciences Chimiques et Biologiques pour la Santé Et de l’unité de recherche INSERM U1183 - Institut de Médecine Régénératrice et de Biothérapie (I.M.R.B.) Spécialité: Biologie Santé Présentée par KHAN Abrar Ul Haq Cellular Metabolism Regulates Anti-Oxidant Response Through ERK5-MEF2 Pathway Rôle de la voie ERK5-MEF2 dans la régulation de la réponse anti-oxydante par le métabolisme cellulaire Soutenue le 27 /06/2017 devant le jury composé de Mme Naomi TAYLOR , DR Président du Jury IGMM, Montpellier Mr Rodrigue ROSSIGNOL , DR Rapporteur MRGM, Bordeaux Mme Sophie VASSEUR , DR Rapporteur CRCM, Marseille Mme Nathalie ANDRIEU , DR Examinateur CRCT, Toulouse Mr Guillaume BOSSIS , CR Examinateur IGMM, Montpellier Mr Martin VILLALBA , DR, Directeur de thèse I.R.M.B. Montpellier ! ACKNOWLEDGMENT First and foremost I am obliged to the almighty ALLAH, for showering HIS blessings and enabling me for this honor. Without any doubt I would like to present my amplest gratefulness to Dr. Martin Villalba for his kind supervision and scientific guidance throughout my PhD research. His supportive attitude always gave me extraordinary confidence during theses nerve testing process. I always found unflinching encouragement and support from him. I will not hesitated to mention that his pleasant scientist’s intuition built in me a constant oasis of ideas and cravings of science, which exceptionally inspire and enrich my growth as a student, a researcher and a scientist. I am beholden to him beyond his consideration. I simply cannot wish for a better and friendlier supervisor. Martin you never behaved with a bossy attitude and your office door was always open for me and I never felt hesitant to discuss any issue I faced regarding science or in person, bundle of thanks for fullest support. I deem it paramount pleasure to avail this occasion to express the sincerest gratitude and a deep sense of obligation to Martin for his nimble leadership, analytical arbitration, compassionate insolence and inspirational determinations to indoctrinate in me the spirit of scientific motivation and developed writing dexterities during the course of my research work. I perhaps do not have superior words to definite my inner sensation and appreciativeness towards you. I am obliged to the “Higher Education Commission (HEC)” of Pakistan, its officers and officials for funding my doctorates study in France within their limited resources. I am also thankful to CHU Montpellier for funding my last year of thesis. I must also mention the services provided by Campus France to facilitate my living in France. I zealously extend my profound thanks to the participants of my thesis jury Mme Naomi Taylor, Mr. Rodrigue Rossignol, Mme Sophie Vasseur, Mme Nathalie Andrieu, Mr. Guillaume Bossis and once again to my thesis director. I would also not forget to reflect my gratitude to Delphine Gitenay, Nerea Allende- Vega, Dang-Nghiem Vo, Sana Belkahla, Catherine Alexia, Cecile Saout, Javier Hernandez, Amelie Carnillon and former lab members Moeez Ghani, Ewelina ! krzywinska, Nuria Lopez, Diego Sanchez, Ludovic Gabellier, Gabriel Espinosa and Johan Garaude for their teamwork and livelihood in every aspect. I will especially thanks to Sabine Gerbal, Claire Gondeau, Martine Daujat and Charles Lecillier for their support in my work regarding lipid metabolism and miRNA. I am also indebted to my all colleagues and administration of Institute for Regenerative Medicine and Biotherapy (IRMB) U1183 INSERM and I would like to imitate my gratitude especially to Prof. Christian Jorgensen who is leading the institute from the front. Finally, I will always be indebted to my family particularly to my mother for her countless prayers. My unpretentious recognitions are to all my family members who were always there for my support throughout my study. I will dedicate this thesis in honor to my late father (RIP). ! Table of Contents Abbreviations ........................................................................................................................ 1 Abstract ................................................................................................................................. 3 Résumé .................................................................................................................................. 5 1. Metabolism ............................................................................................................ 8 1.1. Cellular Respiration .................................................................................................. 9 1.1.1. Glucose Metabolism ............................................................................................. 9 1.1.2. Fructose Metabolism .......................................................................................... 11 1.1.3. Galactose Metabolism ........................................................................................ 12 1.1.4. The Krebs cycle (Citric acid cycle or Tricarboxylic acid cycle) ........................ 13 1.1.5. Oxidative phosphorylation (OXPHOS) .............................................................. 14 1.2. Lactic acid Fermentation ........................................................................................ 17 1.3. Glutaminolysis .......................................................................................................... 17 1.3.1. Glutamine metabolism and cancer ...................................................................... 18 1.4. Lipid metabolism ..................................................................................................... 20 1.4.1. Lipid metabolism and cancer .............................................................................. 21 1.5. Tumor metabolism ................................................................................................... 22 2. Dichloroacetate .................................................................................................... 29 2.1. Dichloroacetate in Cancer ....................................................................................... 31 2.2. DCA and Lipids homeostasis .................................................................................. 37 3. Cellular Signaling ............................................................................................... 41 3.1. MAPK Extra Regulated Kinase 5 (ERK5) ............................................................ 43 3.1.1. Structure of ERK5 .............................................................................................. 43 3.1.2. Activation of ERK5 ............................................................................................ 44 3.2. Biological Roles of ERK5 ........................................................................................ 46 3.3. ERK5 in Cancer ....................................................................................................... 47 3.3.1. Oncogenes and ERK5 ......................................................................................... 47 3.3.2. ERK5 and Tumorigenesis ................................................................................... 48 3.3.3. ERK5 and leukemia ............................................................................................ 48 3.3.4. ERK5 and Tumor progression ............................................................................ 49 3.3.5. ERK5 and tumor metastasis ................................................................................ 50 3.3.6. ERK5 and tumor resistance to cell death ............................................................ 50 3.3.7. ERK5 and Tumor associated angiogenesis ......................................................... 52 3.4. ERK5 and Tumor suppressive miRNAs ................................................................ 52 3.5. Inhibitors of MEK5/ERK5 ...................................................................................... 53 4. Cellular Redox Homeostasis .............................................................................. 57 4.1. NFE2L2 (NRF2) ....................................................................................................... 57 4.2. KEAP1 ...................................................................................................................... 58 4.3. Regulation of NRF2/KEAP1 Pathway ................................................................... 59 4.4. NRF2 Response mechanism ...................................................................................
Load more

Recommended publications
  • Steady State and Transient Behavior of a Continuous Fermentor Thor Almep R Hanson Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1969 Steady state and transient behavior of a continuous fermentor Thor almeP r Hanson Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Chemical Engineering Commons Recommended Citation Hanson, Thor almeP r, "Steady state and transient behavior of a continuous fermentor " (1969). Retrospective Theses and Dissertations. 4109. https://lib.dr.iastate.edu/rtd/4109 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. 70-13,589 HANSONJ Thor Palmer, 1942- STEADY STATE AND TRANSIENT BEHAVIOR OF A CONTINUOUS FERMENTOR. Iowa State University, Ph.D., 1969 Engineering, chemical University Microfilms, Inc., Ann Arbor, Michigan THIS DISSERTATION HAS BEEN MICROFILMED EXACTLY AS RECEIVED STEADY STATE AND TRANSIENT BEHAVIOR OF A CONTINUOUS FERMENTOR Thor Palmer Hanson A Dissertation Submitted to the Graduate Faculty in Partial Fulfillment of The Requirements for the Degree of DOCTOR OP PHILOSOPHY Major Subject: Chemical Engineering Approved : Signature was redacted for privacy. In Charge of Major Work Signature was redacted for privacy. Head of Major Department Signature was redacted for privacy. D( 'ége Iowa State University Ames, lowa 1969 11 TABLE OP CONTENTS Page ABSTRACT v I. INTRODUCTION 1 II. BACKGROUND INFORMATION 5 A. Bacterial Growth 5 B. Mathematical Models for Bacterial Growth l4 1.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050221029A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0221029 A1 Cater et al. (43) Pub. Date: Oct. 6, 2005 (54) OXYGEN SCAVENGING SYSTEM Publication Classi?cation (76) Inventors: Mark W. Cater, Prairie, MN (US); (51) Int. Cl? ..................................................... .. B65D 1/00 Donald A. Grindsta?', Apple Valley, (52) US. Cl. .......................................................... .. 428/341 MN (US) (57) ABSTRACT Correspondence Address: The oxygen scavenging system of the subject invention NAWROCKI, ROONEY & SIVERTSON contemplates a composition, system and appurtenant meth SUITE 401, BROADWAY PLACE EAST odology for substantially eliminating elemental oxygen 3433 BROADWAY STREET NORTHEAST from packaged oxygen sensitive products. The composition MINNEAPOLIS, MN 554133009 or scavenging agent includes an oxidoreductase enZyme, a suitable energy source or substrate for the enZyme, and a (21) Appl. No.: 10/518,292 buffer. The composition binds oxygen When exposed to moisture, thereby reducing the level of oxygen in a closed (22) PCT Filed: Jun. 17, 2003 (e.g., sealed) space such as a food package or the like. More particularly and preferably, the composition includes glu (86) PCT No.: PCT/US03/19029 cose oxidase in an amount of betWeen 1 and 100 activity units (U) per gram, catalase in an amount of betWeen 1 and Related US. Application Data 300 activity units (U) per gram, dextrose in an amount of betWeen about 20 and 99 percent by Weight, and sodium (60) Provisional application No. 60/389,246, ?led on Jun. bicarbonate in an amount of betWeen about 1 and 80 percent 17, 2002. by Weight. US 2005/0221029 A1 Oct. 6, 2005 OXYGEN SCAVENGING SYSTEM or sachets.
    [Show full text]
  • Cell Type–Dependent Effects of Polo-Like Kinase 1 Inhibition Compared with Targeted Polo Box Interference in Cancer Cell Lines
    3189 Cell type–dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines Jenny Fink, Karl Sanders, Alexandra Rippl, certain cell lines but highly contrasting effects in others. Sylvia Finkernagel, Thomas L. Beckers, This may point to subtle differences in the molecular and Mathias Schmidt machinery of mitosis regulation in cancer cells. [Mol Cancer Ther 2007;6(12):3189–97] Nycomed GmbH, Konstanz, Germany Introduction Abstract Polo-like kinase 1 (Plk1) has been identified as key player Multiple critical roles within mitosis have been assigned for G2-M transition and mitotic progression in both normal to Polo-like kinase 1 (Plk1), making it an attractive and tumor cells (1). Multiple roles have been assigned to candidate for mitotic targeting of cancer cells. Plk1 Plk1 at the entry into M phase, mitotic spindle formation, contains two domains amenable for targeted interference: condensation and separation of chromosomes, exit from a kinase domain responsible for the enzymatic function mitosis by activation of the anaphase-promoting complex, and a polo box domain necessary for substrate recogni- and in cytokinesis (reviewed in ref. 2). Moreover, recent tion and subcellular localization. Here, we compare two reports implicated an involvement of Plk1 in the resump- approaches for targeted interference with Plk1 function, tion of cell cycle reentry after checkpoint activation through either by a Plk1 small-molecule enzyme inhibitor or by DNA-damaging agents (3). It is therefore not surprising inducible overexpression of the polo box in human cancer that targeted interference with Plk1, primarily by anti- cell lines.
    [Show full text]
  • Fermentation Microorganisms and Flavor Changes in Fermented Foods R.F
    Fermentation Technology—12th World Congress of Food Science and Technology Fermentation Microorganisms and Flavor Changes in Fermented Foods R.F. MCFEETERS ABSTRACT: Food fermentation processes often result in profound changes in flavor relative to the starting ingredients. However, fermenting foods are typically very complex ecosystems with active enzyme systems from the ingredient materials interacting with the metabolic activities of the fermentation organisms. Factors such as added salt, particle sizes, temperature, and oxygen levels will also have important effects on the chemistry that occurs during fermentation. This is a brief review of recent research on flavor changes in food fermentations. The emphasis will be on the role of lactic acid bacteria in changing the compounds that help determine the character of fermented foods from plant-based substrates. Introduction GC-olfactometry led to recognition of a compound with an odor actic acid bacteria influence the flavor of fermented foods in a close to that of the fermentation brine. The compound with a fer- Lvariety of ways. In many cases, the most obvious change in a lac- mentation brine odor was identified as trans-4-hexenoic acid. They tic acid fermentation is the production of acid and lowering pH that also tentatively identified the presence of cis-4-hexenoic acid. In a results in an increase in sourness. Since most of the acid produced reconstitution experiment, a solution that contained 25 ppm trans- in fermentations will be produced by the metabolism of sugars, 4-hexenoic acid, 10 ppm phenyl ethyl alcohol, 0.65% lactic acid, sweetness will likely decrease as sourness increases. The produc- 0.05% acetic acid, and 8% NaCl had an odor very similar to that of tion of volatile flavor components tends to be the first mechanism brine from fermented cucumbers.
    [Show full text]
  • Mutant P53 Protects Cells from 12-O-Tetradecanoylphorbol-13- Acetate–Induced Death by Attenuatingactivating Transcription Factor 3 Induction
    Research Article Mutant p53 Protects Cells from 12-O-Tetradecanoylphorbol-13- Acetate–Induced Death by AttenuatingActivating Transcription Factor 3 Induction Yosef Buganim,1 Eyal Kalo,1 Ran Brosh,1 Hila Besserglick,1 Ido Nachmany,3 Yoach Rais,2 Perry Stambolsky,1 Xiaohu Tang,1 Michael Milyavsky,1 Igor Shats,1 Marina Kalis,1 Naomi Goldfinger,1 and Varda Rotter1 1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; 2Department of Life Science, Bar-Ilan University, Ramat Gan, Israel; and 3Department of General Surgery B, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Abstract mutated. Notably, the predominant mode of p53 inactivation is by Mutations in p53 are ubiquitous in human tumors. Some p53 point mutation rather than by deletion or truncation. These data mutations not only result in loss of wild-type (WT) activity but coupled with the observation that mutant p53 is generally highly also grant additional functions, termed ‘‘gain of function.’’ overexpressed in tumors have led to the hypothesis that mutant In this study, we explore how the status of p53 affects the p53 possesses gain-of-function activities. This hypothesis is immediate response gene activating transcription factor 3 supported by the results of in vivo and in vitro studies. For (ATF3) in the 12-O-tetradecanoylphorbol-13-acetate (TPA)- example, mice harboring mutant p53 display allele-specific tumor protein kinase C (PKC) pathway. We show that high doses of spectra, higher metastatic frequency, enhanced cell proliferation, TPA induce ATF3 in a WT p53-independent manner correlat- and higher transformation potential compared with their p53-null ingwith PKCs depletion and cell death.
    [Show full text]
  • Action on Muscle Metabolism and Insulin Sensitivity E Strong Enough for a Man, Made for a Woman
    Review The impact of ERa action on muscle metabolism and insulin sensitivity e Strong enough for a man, made for a woman Andrea L. Hevener*, Zhenqi Zhou, Timothy M. Moore, Brian G. Drew, Vicent Ribas ABSTRACT Background: The incidence of chronic disease is elevated in women after menopause. Natural variation in muscle expression of the estrogen receptor (ER)a is inversely associated with plasma insulin and adiposity. Moreover, reduced muscle ERa expression levels are observed in women and animals presenting clinical features of the metabolic syndrome (MetSyn). Considering that metabolic dysfunction impacts nearly a quarter of the U.S. adult population and elevates chronic disease risk including type 2 diabetes, heart disease, and certain cancers, treatment strategies to combat metabolic dysfunction and associated pathologies are desperately needed. Scope of the review: This review will provide evidence supporting a critical and protective role for skeletal muscle ERa in the regulation of metabolic homeostasis and insulin sensitivity, and propose novel ERa targets involved in the maintenance of metabolic health. Major conclusions: Studies identifying ERa-regulated pathways essential for disease prevention will lay the important foundation for the rational design of novel therapeutics to improve the metabolic health of women while limiting secondary complications that have plagued traditional hormone replacement interventions. Ó 2018 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Keywords Estrogen action; Estrogen receptors; Insulin sensitivity; Metabolic homeostasis 1. INTRODUCTION new-onset T2DM in postmenopausal women following HRT compared with placebo [7]. The mechanism by which HRT reduces T2D incidence For over two decades researchers have shown strong relationships in postmenopausal women is not yet known however molecular between estrogen action and metabolic health in women.
    [Show full text]
  • Review Article Mitotic Kinases and P53 Signaling
    Hindawi Publishing Corporation Biochemistry Research International Volume 2012, Article ID 195903, 14 pages doi:10.1155/2012/195903 Review Article Mitotic Kinases and p53 Signaling Geun-Hyoung Ha1 and Eun-Kyoung Yim Breuer1, 2 1 Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA 2 Department of Molecular Pharmacology and Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA Correspondence should be addressed to Eun-Kyoung Yim Breuer, [email protected] Received 6 April 2012; Accepted 18 May 2012 Academic Editor: Mandi M. Murph Copyright © 2012 G.-H. Ha and E.-K. Y. Breuer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Mitosis is tightly regulated and any errors in this process often lead to aneuploidy, genomic instability, and tumorigenesis. Deregulation of mitotic kinases is significantly associated with improper cell division and aneuploidy. Because of their importance during mitosis and the relevance to cancer, mitotic kinase signaling has been extensively studied over the past few decades and, as a result, several mitotic kinase inhibitors have been developed. Despite promising preclinical results, targeting mitotic kinases for cancer therapy faces numerous challenges, including safety and patient selection issues. Therefore, there is an urgent need to better understand the molecular mechanisms underlying mitotic kinase signaling and its interactive network. Increasing evidence suggests that tumor suppressor p53 functions at the center of the mitotic kinase signaling network. In response to mitotic spindle damage, multiple mitotic kinases phosphorylate p53 to either activate or deactivate p53-mediated signaling.
    [Show full text]
  • Α-Synuclein-Sy-Synucleinnuclein Phosphorylationphosphorylation Andand Re Relatedlated Kinaseskinases Inin Parkinsonparkinson’S Diseasedisease
    αα-Synuclein-Sy-Synucleinnuclein phosphorylationphosphorylation andand relatedrelated kinaseskinases inin ParkinsonParkinson’s diseasedisease Jin-XiaJin-Xia ZhouZhou A thesis submitted in fulfillment of the requirement of the degree of Doctor of Philosophy School of Medical Sciences, Faculty of Medicine and Neuroscience Research Australia November 2013 I PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Zhou First name: Jin-Xia Other name/s: I Abbreviation for degree as given in the University calendar: PhD School: School of Medical Sciences Faculty: Medicine lation and related kinases in Parkinson's disease Abstract 350 words maximum: (PLEASE TYPE) ' Parkinson's disease (PO) is the most common neurodegenerative movement disorder pathologically identified by degeneration of the nigrostriatal system and the presence of Lcwy bodies (LBs) and neurites. structuTal pathologies largely made from insoluble a-synuclein phosphorylated at serine 129 (S 129P). Several kinases have been suggested to facilitate a-synuciein phosphorylation in PD, but without significant human data the changes that precipitate such pathology remain conjecture. The major aims of this pr~ject were to assess the dynamic changes of a -synuclein phosphorylation and related kinases in the progression of PD and in animal models of PD. and to determine whether Tenuigenin (TEN), a Chinese medicinal herb, can prevent cc-synucleln-induc.?d toxicity in a cell model. The levels of non-phosphorylated a-synuclein decreased over the course ofPD, becoming increasingly phosphorylated and insoluble. There was a dramatic increase in phosphorylated a-synuclein that preceded LB formation. Importantly, three a-synuc!ein-relatec ki nases [polo-like kinase 2 {PLK2), lcuc.:inc- rich repeat kinase 2 (LRRK2l and cyclin G-~tssoc i ated kinase (GAK)] were found to be involved at different times in the evolution of LB formation in P.O.
    [Show full text]
  • An Autoregulatory Loop Controls Peroxisome Proliferator-Activated Receptor Γ Coactivator 1Α Expression in Muscle
    Institutional Repository of the University of Basel University Library Schoenbeinstrasse 18-20 CH-4056 Basel, Switzerland http://edoc.unibas.ch/ Year: 2003 An autoregulatory loop controls peroxisome proliferator-activated receptor γ coactivator 1α expression in muscle Handschin, C. and Rhee, J. and Lin, J. and Tarr, P. T. and Spiegelman, B. M. Posted at edoc, University of Basel Official URL: http://edoc.unibas.ch/dok/A5258732 Originally published as: Handschin, C. and Rhee, J. and Lin, J. and Tarr, P. T. and Spiegelman, B. M.. (2003) An autoregulatory loop controls peroxisome proliferator-activated receptor γ coactivator 1α expression in muscle. Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, H. 12. S. 7111-7116. An Autoregulatory Loop Controls PGC-1 Expression in Muscle Christoph Handschin, James Rhee, Jiandie Lin, Paul T. Tarr, and Bruce M. Spiegelman* Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115 Published in Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7111-6. PMID: 12764228. doi: 10.1073/pnas.1232352100 Copyright © National Academy of Sciences; Proceedings of the National Academy of Sciences USA Page 1 of 24 Classification: Biological Sciences, Cell Biology An Autoregulatory Loop Controls PGC-1 Expression in Muscle Christoph Handschin, James Rhee, Jiandie Lin, Paul T. Tarr, and Bruce M. Spiegelman* Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115 * To whom
    [Show full text]
  • Hexose Oxidase from Chondrus Crispus Expressed in Hansenula Polymorpha
    Chemical and Technical Assessment 63rdJECFA Hexose Oxidase from Chondrus Crispus expressed in Hansenula Polymorpha CHEMICAL AND TECHNICAL ASSESSMENT (CTA) Prepared by Jim Smith and Zofia Olempska-Beer © FAO 2004 1 Summary Hexose oxidase (HOX) is an enzyme that catalyses the oxidation of C6-sugars to their corresponding lactones. A hexose oxidase enzyme produced from a nonpathogenic and nontoxigenic genetically engineered strain of the yeast Hansenula polymorpha has been developed for use in several food applications. It is encoded by the hexose oxidase gene from the red alga Chondrus crispus that is not known to be pathogenic or toxigenic. C. crispus has a long history of use in food in Asia and is a source of carrageenan used in food as a stabilizer. As this alga is not feasible as a production organism for HOX, Danisco has inserted the HOX gene into the yeast Hansenula polymorpha. The information about this enzyme is provided in a dossier submitted to JECFA by Danisco, Inc. (Danisco, 2003). Based on the hexose oxidase cDNA from C. crispus, a synthetic gene was constructed that is more suitable for expression in yeast. The synthetic gene encodes hexose oxidase with the same amino acid sequence as that of the native C. crispus enzyme. The synthetic gene was combined with regulatory sequences, promoter and terminator derived from H. polymorpha, and inserted into the well-known plasmid pBR322. The URA3 gene from Saccharomyces cerevisiae (Baker’s yeast) and the HARS1 sequence from H. polymorpha were also inserted into the plasmid. The URA3 gene serves as a selectable marker to identify cells containing the transformation vector.
    [Show full text]
  • (FAD) and Flavin Mononucleotide (FMN) to Enzymes: the Current State of Affairs
    Protein Science (1998). 77-20. Cambridge University Press. Printed in the USA. Copyright 0 1998 The Protein Society REVIEW Covalent attachment of flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) to enzymes: The current state of affairs MARTIN MEWIES,' WILLIAM S. McINTIRE,~.~AND NIGEL S. SCRUTTON' ' Department of Biochemistry, University of Leicester, Adrian Building, University Road, Leicester LEI 7RH UK * Molecular Biology Division, Department of Veterans Affairs Medical Center, San Francisco, California 94121 Department of Biochemistry and Biophysics and Department of Anesthesia, University of California, San Francisco, California 94565 (RECEIVEDMay 29, 1997; ACCEFTEDJuly 18, 1997) Abstract The first identified covalent flavoprotein, a component of mammalian succinate dehydrogenase, was reported 42 years ago. Since that time, more than 20 covalent flavoenzymes have been described, each possessing one of five modes of FAD or FMN linkage to protein. Despite the early identification of covalent flavoproteins, the mechanisms of covalent bond formation and the roles of the covalent links are only recently being appreciated. The main focus of this review is, therefore, one of mechanism and function, in addition to surveying the types of linkage observed and the methods employed for their identification. Case studies are presented for a variety of covalent flavoenzymes, from which general findings are beginning to emerge. Keywords: covalent flavoproteins; flavin adenine dinucleotide; flavin mononucleotide; flavinylation; redox cofactors Cofactors are recruited by protein molecules to extend the chem- lipoate-protein ligases (Brookfield et al., 1991; Moms et al., 1994), istry available within the active sites of enzymes. The chemistries respectively. In a similar fashion, a heme cytochrome c lyase (Steiner displayed are variable and the range of protein-specific cofactors et al., 1996) is responsible for the covalent addition of heme to two available bears testimony to the types of biological reaction achieved Cys residues via thioether linkages.
    [Show full text]
  • Decreased Biochemical Progression in Patients with Castration‑Resistant
    ONCOLOGY LETTERS 19: 4151-4160, 2020 Decreased biochemical progression in patients with castration‑resistant prostate cancer using a novel mefenamic acid anti‑inflammatory therapy: A randomized controlled trial JOSÉ GUZMAN‑ESQUIVEL1,2, MARTHA A. MENDOZA-HERNANDEZ1, DANIEL TIBURCIO-JIMENEZ1, OSCAR N. AVILA‑ZAMORA3, JOSUEL DELGADO-ENCISO4, LUIS DE-LEON-ZARAGOZA2,3, JUAN C. CASAREZ-PRICE2,3, IRAM P. RODRIGUEZ-SANCHEZ5, MARGARITA L. MARTINEZ-FIERRO6, CARMEN MEZA-ROBLES1,3, ALEJANDRO BAROCIO-ACOSTA3, LUZ M. BALTAZAR-RODRIGUEZ1, SERGIO A. ZAIZAR-FREGOSO1, JORGE E. PLATA-FLORENZANO2,3 and IVÁN DELGADO‑ENCISO1,3 1Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040; 2Department of Research, General Hospital of Zone No. 1 IMSS, Villa de Alvarez, Colima 28983; 3Department of Research, Cancerology State Institute, Colima State Health Services; 4Department of Research, Foundation for Cancer Ethics, Education and Research of The Cancerology State Institute, Colima 28085; 5Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460; 6Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico Received July 19, 2019; Accepted November 13, 2019 DOI: 10.3892/ol.2020.11509 Abstract. Prostate cancer (PCa) is the second most common increase in the placebo group (P=0.024). In the patients treated non-dermatological cancer in men and is a growing public with the placebo, 70% had biochemical disease progression health problem. Castration-resistant disease (CRD) is the most (an increase of ≥25% in PSA levels), which did not occur advanced stage of the disease and is difficult to control.
    [Show full text]